Reviewing Acorda Therapeutics (ACOR) & Sangamo Therapeutics (SGMO)
Acorda Therapeutics (NASDAQ: ACOR) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
This table compares Acorda Therapeutics and Sangamo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Acorda Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500.
Insider and Institutional Ownership
63.5% of Sangamo Therapeutics shares are held by institutional investors. 7.9% of Acorda Therapeutics shares are held by company insiders. Comparatively, 5.5% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Acorda Therapeutics and Sangamo Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acorda Therapeutics currently has a consensus target price of $23.63, suggesting a potential downside of 11.10%. Sangamo Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 20.97%. Given Sangamo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Acorda Therapeutics.
Valuation and Earnings
This table compares Acorda Therapeutics and Sangamo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Acorda Therapeutics||$535.06 million||2.32||$49.45 million||($1.21)||-21.96|
|Sangamo Therapeutics||$23.42 million||44.27||-$57.47 million||($0.81)||-15.31|
Acorda Therapeutics has higher revenue and earnings than Sangamo Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics beats Acorda Therapeutics on 7 of the 13 factors compared between the two stocks.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.